Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ALIM - Alimera's partner Ocumension gets China regulator nod to start diabetic macular edema study

ALIM - Alimera's partner Ocumension gets China regulator nod to start diabetic macular edema study

Alimera Sciences Inc.
Alimera Sciences (NASDAQ:ALIM) its partner Ocumension Therapeutics received approval from China's National Medical Products Administration (NMPA) for an application seeking to begin a phase 3 trial of fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). DME is a complication of diabetes which can lead to vision loss. The company said the investigational new drug (IND) application is for the phase 3 trial, which is aimed at supporting a potential future new drug filing to get approval of the implant in mainland China.

For further details see:

Alimera's partner Ocumension gets China regulator nod to start diabetic macular edema study
Stock Information
Company Name: Alimera Sciences Inc.
Stock Symbol: ALIM
Market: NASDAQ
Website: alimerasciences.com
Menu
ALIM ALIM Quote ALIM Short ALIM News ALIM Articles ALIM Message Board
Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...